Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today ...
A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.
The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the ...
The scientists driving Neion Bio’s effort to engineer chickens as scalable, lower-cost platforms for biologics manufacturing.
The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the emphasis has been on its underlying mechanisms and nucleases. In contrast, ...
Dozens of new discoveries reveal that defenses evolved by bacteria and viruses billions of years ago still define our own ...
The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling ...
When CRISPR cuts a gene flanked by short, repeating DNA sequences, the cell’s repair machinery gets confused. It simply zips ...
The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling precise correction ...
Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precision medicine and fuel rapid market growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results